TY - JOUR
T1 - Therapeutic blockade of platelet-derived growth factor receptor-like protein attenuates cartilage degeneration and modulates cytokines in a spontaneous osteoarthritis mouse model
AU - Ueng, Steve Wen Neng
AU - Hsu, Yung Heng
AU - Lin, Yu Chih
AU - Hu, Chih Chien
AU - Chiu, Yu Tien
AU - Chang, Yuhan
AU - Chen, Mei Feng
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025/10/30
Y1 - 2025/10/30
N2 - Objective: Osteoarthritis (OA) is a prevalent degenerative joint disorder characterized by the progressive breakdown of articular cartilage, affecting 10–15 % of older adults worldwide. There remains an urgent need for effective therapies to prevent chondrocyte loss, extracellular matrix (ECM) degradation, and OA progression. Methods: Through LC-MS/MS-based secretome analysis, we identified platelet-derived growth factor receptor-like protein (PDGFRL) as a novel factor significantly upregulated in osteoarthritic cartilage. To investigate its functional role, we utilized human cartilage plugs, STR/ort mice with spontaneous OA, and primary chondrocyte cultures to model ex vivo, in vivo, and in vitro conditions, respectively, allowing for comprehensive evaluation of PDGFRL's effects on chondrocytes and its underlying mechanisms. Results: PDGFRL expression was markedly elevated in both human and murine osteoarthritic cartilage. In the ex vivo human cartilage plug model, PDGFRL exerted deleterious effects by inducing chondrocyte clustering and reducing SOX9 expression. In vitro, PDGFRL treatment increased phosphorylation of Chk-2, p53, and eNOS, along with IGFBP3 secretion, indicating activation of apoptotic and ECM-degradative pathways. In STR/ort mice, anti-PDGFRL antibody treatment alleviated OA progression by reducing matrix-nonproducing chondrocytes, decreasing OARSI scores, suppressing aggrecan degradation and MMP-13 expression, and restoring SOX9 levels. Additionally, anti-PDGFRL treatment modulated systemic cytokine profiles by increasing chondroprotective IL-13 and IP-10, while elevating cartilage-destructive leptin and IL-7R. In contrast, exogenous PDGFRL protein administration did not exacerbate OA severity. Conclusion: Our findings identify PDGFRL as a therapeutic target, and suggest that inhibition using specific antibodies may offer a novel strategy to preserve cartilage integrity and slow disease progression.
AB - Objective: Osteoarthritis (OA) is a prevalent degenerative joint disorder characterized by the progressive breakdown of articular cartilage, affecting 10–15 % of older adults worldwide. There remains an urgent need for effective therapies to prevent chondrocyte loss, extracellular matrix (ECM) degradation, and OA progression. Methods: Through LC-MS/MS-based secretome analysis, we identified platelet-derived growth factor receptor-like protein (PDGFRL) as a novel factor significantly upregulated in osteoarthritic cartilage. To investigate its functional role, we utilized human cartilage plugs, STR/ort mice with spontaneous OA, and primary chondrocyte cultures to model ex vivo, in vivo, and in vitro conditions, respectively, allowing for comprehensive evaluation of PDGFRL's effects on chondrocytes and its underlying mechanisms. Results: PDGFRL expression was markedly elevated in both human and murine osteoarthritic cartilage. In the ex vivo human cartilage plug model, PDGFRL exerted deleterious effects by inducing chondrocyte clustering and reducing SOX9 expression. In vitro, PDGFRL treatment increased phosphorylation of Chk-2, p53, and eNOS, along with IGFBP3 secretion, indicating activation of apoptotic and ECM-degradative pathways. In STR/ort mice, anti-PDGFRL antibody treatment alleviated OA progression by reducing matrix-nonproducing chondrocytes, decreasing OARSI scores, suppressing aggrecan degradation and MMP-13 expression, and restoring SOX9 levels. Additionally, anti-PDGFRL treatment modulated systemic cytokine profiles by increasing chondroprotective IL-13 and IP-10, while elevating cartilage-destructive leptin and IL-7R. In contrast, exogenous PDGFRL protein administration did not exacerbate OA severity. Conclusion: Our findings identify PDGFRL as a therapeutic target, and suggest that inhibition using specific antibodies may offer a novel strategy to preserve cartilage integrity and slow disease progression.
KW - Chondrocyte
KW - Human cartilage plugs
KW - OARSI score
KW - Platelet-derived growth factor receptor-like (PDGFRL)
KW - SOX9
KW - STR/ort mice
UR - https://www.scopus.com/pages/publications/105012606123
U2 - 10.1016/j.intimp.2025.115294
DO - 10.1016/j.intimp.2025.115294
M3 - 文章
C2 - 40779842
AN - SCOPUS:105012606123
SN - 1567-5769
VL - 164
SP - 115294
JO - International Immunopharmacology
JF - International Immunopharmacology
M1 - 115294
ER -